Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales
Open Access
- 26 September 2025
- journal article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (12) , 3273-3277
Abstract
Background: Aztreonam/avibactam is a novel β-lactam/β-lactamase inhibitor (BL/BLI) combination active against carbapenem-resistant Enterobacterales (CRE), including MBL-producing isolates. In May 2024, EUCAST published Enterobacterales breakpoints for aztreonam/avibactam. This study aimed to assess the performance of commercially available disc diffusion (DD) against broth microdilution (BMD) using the latest EUCAST breakpoints. Methods: We tested 278 CRE causing infections in 17 Greek ICUs between 2021 and 2023, using 30/20 μg aztreonam/avibactam discs and BMD according to EUCAST methodology and EUCAST version 15.0 breakpoints. Results: Most isolates were identified as Klebsiella pneumoniae (97.8%), and 98.9% produced carbapenemases, including 46.4% KPC, 20.1% NDM, 5.4% VIM and 27% multiple carbapenemases. Using BMD, 94.2% of isolates were susceptible to aztreonam/avibactam. Conversely, using DD, 66.9% were susceptible, 33.1% resistant and 27% within the area of technical uncertainty (ATU). Most isolates in the ATU were KPC-producing (68%) or KPC and MBL-producing (29.3%). All isolates in the ATU (22–24 mm) tested susceptible by BMD (MIC ≤ 4 mg/L). One isolate exhibited resistance by DD (20 mm), but was susceptible by BMD. Categorical agreement (CA) was 72.7%, with 29% major errors (MEs) and 0% very major errors (VMEs). Using a breakpoint of 22 mm, CA, ME and VME were 99.6%, 0.4% and 0%, respectively. Conclusions: Aztreonam/avibactam showed potent in vitro activity against MBL- and KPC-producing Enterobacterales. Using the 2025 EUCAST breakpoint, all isolates in the ATU tested susceptible by BMD, leading to high MEs of the DD method. A 22 mm breakpoint would have corrected this discrepancy in our cohort.Keywords
Funding Information
- Wellcome Trust (226007/Z/22/Z)
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (1R01AI146338)
- GOSH/ICH Biomedical Research Centre
This publication has 10 references indexed in Scilit:
- Aztreonam–avibactam: The dynamic duo against multidrug‐resistant gram‐negative pathogensPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024
- Evaluation of gradient strip diffusion for susceptibility testing of aztreonam–avibactam in metallo-β-lactamase-producing EnterobacteralesJournal of Clinical Microbiology, 2024
- Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?Journal of Antimicrobial Chemotherapy, 2024
- Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacteralesBMC Infectious Diseases, 2024
- Performance of disk diffusion method for aztreonam in combination with avibactam against EnterobacterialesJournal of Antimicrobial Chemotherapy, 2024
- Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosaAntibiotics, 2024
- Antimicrobial Resistance Laboratory Network’s multisite evaluation of the ThermoFisher Sensititre GN7F broth microdilution panel for antimicrobial susceptibility testingJournal of Clinical Microbiology, 2023
- Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coliInternational Journal of Antimicrobial Agents, 2023
- Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase–Producing EnterobacteralesClinical Infectious Diseases, 2020
- CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility TestsJournal of Clinical Microbiology, 2018